text
"['\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 백만원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\nHPI, INC.\n2007.08.29\n1 Church St. Suite #103Rockville, MD. 20850 USA\n해외임상시험\n451\n지분율50%초과\nX\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n한올바이오파마(주)\n164111-0000397\n(주)대웅\n131111-0000271\n(주)대웅제약\n134811-0075342\n비상장\n31\n대웅바이오(주)\n134811-0172221\n(주)대웅생명과학\n210111-0013294\n(주)대웅경영개발원\n110111-0776463\n(주)대웅이엔지\n134811-0034421\n(주)대웅개발\n131111-0083649\n(주)아이디에스앤트러스트\n110111-1234006\n㈜에이치알그룹\n110111-2041872\n(주)대웅테라퓨틱스\n135811-0360271\n(주)힐리언스\n110111-3265778\n(주)대웅인베스트먼트\n110111-8587862\n다나아데이터㈜\n110111-6935790\n농업회사법인(주)대웅낙원\n141411-0009986\n(주)아피셀테라퓨틱스\n134511-0431912\n(주)아이엔테라퓨틱스\n134511-0459592\n(주)대웅펫\n110111-7040457\nDaewoong Pharma PHILIPPINES INC.\n-\n북경대웅위업의약과기유한공사\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\n-\nDaewoong America, Inc.\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.Ltd\n-\n사천대웅생물기술유한공사\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n-\nDaewoong Pharmaceutical India Pvt.,Ltd\n-\nDaewoong Pharmaceutical Japan Co., Ltd.\n-\nHPI,INC\n-\n요녕대웅제약유한공사\n-\nPT. DAEWOONG INFION\n-\nDaewoong Bio Indonesia\n-\nDaewoong Innovation Holdings\n-\nDaewoong Biologics Indonesia\n-\nPT. SELATOX BIO PHARMA\n-\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2024년 06월 30일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nHPI, INC.\n비상장\n2007.09.14\n해외임상시험\n187\n200,200\n100.00\n75\n-\n-\n-\n200,200\n100.00\n75\n721\n265\nImmunoMet Therapeutics, Inc\n비상장\n2015.08.24\n투자\n4,178\n1,285,412\n15.95\n2,701\n-\n-\n-\n1,285,412\n15.95\n2,701\n3,088\n-1,720\nImmunovant, Inc.\n상장\n2019.01.11\n투자\n5,609\n939,395\n0.65\n51,030\n-\n-\n-16,578\n939,395\n0.65\n34,452\n819\n-118\nNurron Pharmaceuticals, Inc\n비상장\n2021.07.19\n공동연구 추진\n571\n58,343\n2.21\n571\n-\n-\n-\n58,343\n2.21\n571\n2,273\n-693\nAlloplex Biotherapeutics Inc.\n비상장\n2021.07.29\n투자\n788\n9,793\n0.38\n788\n-\n-\n-\n9,793\n0.38\n788\n4,810\n-1,069\n대웅인베스트먼트 바이오투자조합1호\n비상장\n2023.07.21\n투자\n1,000\n5,000\n25.00\n1,000\n-\n-\n-\n5,000\n25.00\n1,000\n3,683\n-242\nFreemind Investments L.P.(*)\n비상장\n2023.05.31\n투자\n661\n-\n-\n661\n-\n-\n-\n-\n-\n661\n2,611\n-\nInteron Laboratires, Inc(*)\n비상장\n2023.01.20\n투자\n618\n-\n-\n618\n-\n-\n-\n-\n-\n618\n4,622\n-1,834\nTurnBio technologies, Inc.\n비상장\n2022.04.01\n투자\n1,565\n1,466,072\n2.52\n1,643\n2,331,817\n2,729\n-\n3,797,889\n6.34\n4,372\n7,791\n-7,644\n차세대 지역 뉴딜&바이오투자조합(*)\n비상장\n2022.11.01\n투자\n700\n700\n5.00\n700\n-\n-\n-\n700\n5.00\n700\n13,599\n-478\n합 계\n3,964,915\n-\n59,787\n2,331,817\n2,729\n-16,578\n6,296,732\n-\n45,938\n44,017\n-13,533\n(*)\n재무현황은 23년 기말 재무제표 기준입니다.\n']"
